{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:12:53Z","timestamp":1791166373183,"version":"4.1.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01052-z","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:37:49Z","timestamp":1784871469000},"page":"859-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-8913","authenticated-orcid":false,"given":"Enno","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-1302","authenticated-orcid":false,"given":"Marta Ferrer","family":"Puga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"9","key":"1052_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/jdv.20102","volume":"38","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Pereira MP, Zeidler C, Legat FJ, Misery L, L\u00f6nndahl L, et al. EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: current challenges and future solutions. J Eur Acad Dermatol Venereol. 2024;38(9):1687\u201393. https:\/\/doi.org\/10.1111\/jdv.20102.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1052_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijd.17707","volume":"64","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Hawkes JE, DiRuggiero D, Pansch LA, Simcox E, Gonzalez T. Type 2 inflammation and its role in dermatologic diseases. Int J Dermatol. 2025;64(6):978\u201391. https:\/\/doi.org\/10.1111\/ijd.17707.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1052_CR3","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","volume":"75","author":"CA Akdis","year":"2020","unstructured":"Akdis CA, Arkwright PD, Br\u00fcggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582\u2013605. https:\/\/doi.org\/10.1111\/all.14318.","journal-title":"Allergy"},{"issue":"1","key":"1052_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"key":"1052_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Juntilla","year":"2018","unstructured":"Juntilla IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. https:\/\/doi.org\/10.3389\/fimmu.2018.00888.","journal-title":"Front Immunol"},{"issue":"5","key":"1052_CR6","doi-asserted-by":"publisher","first-page":"73344","DOI":"10.1016\/s1074-7613(02)00317-5","volume":"16","author":"J Zhu","year":"2002","unstructured":"Zhu J, Guo L, Min B, Watson CJ, Hu-Li J, Young HA, et al. Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity. 2002;16(5):73344. https:\/\/doi.org\/10.1016\/s1074-7613(02)00317-5.","journal-title":"Immunity"},{"issue":"1","key":"1052_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signalling pathways to mediate chronic itch. Cell. 2017;171(1):217\u201328.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"4","key":"1052_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI116015","volume":"90","author":"AE Postlethwaite","year":"1992","unstructured":"Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest. 1992;90(4):1479\u201385. https:\/\/doi.org\/10.1172\/JCI116015.","journal-title":"J Clin Invest"},{"issue":"6","key":"1052_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1189\/jlb.1209772","volume":"87","author":"S Chapoval","year":"2010","unstructured":"Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type 2 (Th2)\/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol. 2010;87(6):1011\u20138. https:\/\/doi.org\/10.1189\/jlb.1209772.","journal-title":"J Leukoc Biol"},{"issue":"11","key":"1052_CR10","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.3390\/jcm9113741","volume":"9","author":"M Furue","year":"2020","unstructured":"Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4-JAK-STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020;9(11):3741. https:\/\/doi.org\/10.3390\/jcm9113741.","journal-title":"J Clin Med"},{"issue":"7","key":"1052_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071531","volume":"12","author":"K Antosz","year":"2024","unstructured":"Antosz K, Batko J, B\u0142a\u017cejewska M, Gawor A, Sleziak J, Gomu\u0142ka K. Insight into IL-5 as a potential target for the treatment of allergic diseases. Biomedicines. 2024;12(7):1531. https:\/\/doi.org\/10.3390\/biomedicines12071531.","journal-title":"Biomedicines"},{"issue":"2","key":"1052_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2013.10.048.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1052_CR13","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12(1):5947. https:\/\/doi.org\/10.1038\/s41467-021-26099-w.","journal-title":"Nat Commun"},{"issue":"16","key":"1052_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20164053","volume":"20","author":"S Miake","year":"2019","unstructured":"Miake S, Tsuji G, Takemura M, Hashimoto-Hachiya A, Vu YH, Furue M, et al. IL-4 augments IL-31\/IL-31 receptor alpha interaction leading to enhanced Ccl 17 and Ccl 22 production in dendritic cells: implications for atopic dermatitis. Int J Mol Sci. 2019;20(16):4053. https:\/\/doi.org\/10.3390\/ijms20164053.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1052_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","volume":"22","author":"I Ogulur","year":"2025","unstructured":"Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(3):211\u201342. https:\/\/doi.org\/10.1038\/s41423-025-01261-2.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"1052_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030303","volume":"9","author":"S Garcovich","year":"2021","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines. 2021;9(3):303. https:\/\/doi.org\/10.3390\/vaccines9030303.","journal-title":"Vaccines"},{"key":"1052_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1258823","volume":"16","author":"MR Mack","year":"2023","unstructured":"Mack MR, Miron Y, Chen F, Miller PE, Zhang A, Korotzer A, et al. Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli. Front Mol Neurosci. 2023;16:1258823. https:\/\/doi.org\/10.3389\/fnmol.2023.1258823.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"1052_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2024;153(4):879\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1052_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","volume":"145","author":"SG Kwatra","year":"2025","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O\u2019Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Invest Dermatol. 2025;145(2):249\u201356. https:\/\/doi.org\/10.1016\/j.jid.2024.06.1276.","journal-title":"J Invest Dermatol"},{"key":"1052_CR20","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Luger TA. NK-1 antagonists and itch. In: Cowan A, Yosipovitch G, editors. Pharmacology of itch. Handbook of experimental pharmacology, vol 226. Berlin, Heidelberg: Springer; 2015. p. 237\u201355.","DOI":"10.1007\/978-3-662-44605-8_14"},{"issue":"7542","key":"1052_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature14022","volume":"519","author":"BD Mcneil","year":"2015","unstructured":"Mcneil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237\u201341. https:\/\/doi.org\/10.1038\/nature14022.","journal-title":"Nature"},{"issue":"9","key":"1052_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/exd.14401","volume":"30","author":"G Ingrasci","year":"2021","unstructured":"Ingrasci G, Lipman ZM, Hawash AA, Girolomoni G, Yosipovitch G. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp Dermatol. 2021;30(9):1208\u201317. https:\/\/doi.org\/10.1111\/exd.14401.","journal-title":"Exp Dermatol"},{"issue":"24","key":"1052_CR23","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"5","key":"1052_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390. https:\/\/doi.org\/10.1038\/s41591-023-02320-9.","journal-title":"Nat Med"},{"key":"1052_CR25","unstructured":"Dupixent: highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761055s070lbl.pdf. Accessed 28 Apr 2026."},{"issue":"1","key":"1052_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"10451","key":"1052_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, Tha\u00e7i D, Legat FJ, Papp KA, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(24)01203-0.","journal-title":"Lancet"},{"issue":"2","key":"1052_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","volume":"161","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial. JAMA Dermatol. 2025;161(2):147\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4796.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1052_CR29","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"3","key":"1052_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour J-P, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"5\u20136","key":"1052_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1159\/000540480","volume":"240","author":"D Bahloul","year":"2024","unstructured":"Bahloul D, Dubucq H, Thomas RB, Ajith A, Boss J, Fotheringham I, et al. Burden of disease of bullous pemphigoid: a targeted literature review. Dermatology. 2024;240(5\u20136):823\u201332. https:\/\/doi.org\/10.1159\/000540480.","journal-title":"Dermatology"},{"issue":"1","key":"1052_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers. 2025;11(1):12. https:\/\/doi.org\/10.1038\/s41572-025-00595-5.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1052_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","volume":"29","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011;29(3):427\u201338. https:\/\/doi.org\/10.1016\/j.det.2011.03.010.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1052_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","volume":"78","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989\u201395.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.035.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1052_CR35","doi-asserted-by":"publisher","first-page":"938","DOI":"10.5114\/ada.2020.102111","volume":"37","author":"A Kalinska-Bienias","year":"2020","unstructured":"Kalinska-Bienias A, Kowalczyk E, Jagielski P, Lesniewska A, Komorowska A, Kowalewski C, et al. Clinical characteristics of pruritus in patients with bullous pemphigoid: a preliminary questionnaire-based study. Postepy Dermatol Alergol. 2020;37(6):938\u201342. https:\/\/doi.org\/10.5114\/ada.2020.102111.","journal-title":"Postepy Dermatol Alergol."},{"issue":"9863","key":"1052_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4.","journal-title":"Lancet"},{"issue":"3","key":"1052_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"SM Langan","year":"2011","unstructured":"Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131(3):631\u20136. https:\/\/doi.org\/10.1038\/jid.2010.357.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1052_CR38","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/exd.13401","volume":"26","author":"A-K F\u00f6rsti","year":"2017","unstructured":"F\u00f6rsti A-K, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid: more than skin deep? Exp Dermatol. 2017;26(12):1228\u201334. https:\/\/doi.org\/10.1111\/exd.13401.","journal-title":"Exp Dermatol"},{"key":"1052_CR39","doi-asserted-by":"publisher","first-page":"1196999","DOI":"10.3389\/fimmu.2023.1196999","volume":"14","author":"J Huttelmaier","year":"2023","unstructured":"Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol. 2023;14:1196999. https:\/\/doi.org\/10.3389\/fimmu.2023.1196999.","journal-title":"Front Immunol"},{"issue":"11","key":"1052_CR40","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/jdv.18414","volume":"36","author":"HO Dikmen","year":"2022","unstructured":"Dikmen HO, Yilmaz K, Benoit S, Bernard P, Drenovska K, Gerdes S, et al. Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. J Eur Acad Dermatol Venereol. 2022;36(11):2181\u20139. https:\/\/doi.org\/10.1111\/jdv.18414.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1052_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","volume":"156","author":"S-D Liu","year":"2020","unstructured":"Liu S-D, Chen W-T, Chi C-C. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(8):891\u2013900. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1587.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1052_CR42","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689\u2013704. https:\/\/doi.org\/10.1111\/jdv.18220.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1052_CR43","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, Gl\u00e4ser R, Hertl M, Pfeiffer C, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299\u2013305. https:\/\/doi.org\/10.1111\/bjd.15649.","journal-title":"Br J Dermatol"},{"issue":"10079","key":"1052_CR44","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(17)30560-3.","journal-title":"Lancet"},{"issue":"2","key":"1052_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174\u20138. https:\/\/doi.org\/10.1001\/archderm.136.2.174.","journal-title":"Arch Dermatol"},{"issue":"12","key":"1052_CR46","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.3390\/jcm9123928","volume":"9","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Holtsche MM, Schmidt E, Hammers CM, Zillikens D, Ludwig RJ, et al. Presence of cutaneous complement deposition distinguishes between immunological and histological features of bullous pemphigoid: insights from a retrospective cohort study. J Clin Med. 2020;9(12):3928. https:\/\/doi.org\/10.3390\/jcm9123928.","journal-title":"J Clin Med"},{"key":"1052_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912876","volume":"13","author":"C Cole","year":"2022","unstructured":"Cole C, Vinay K, Borradori L, Amber KT. Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms. Front Immunol. 2022;13:912876. https:\/\/doi.org\/10.3389\/fimmu.2022.912876.","journal-title":"Front Immunol"},{"key":"1052_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973702","volume":"13","author":"C Papara","year":"2022","unstructured":"Papara C, Karsten CM, Ujiie H, Schmidt E, Schmidt-Jim\u00e9nez LF, Baican A, et al. The relevance of complement in pemphigoid diseases: a critical appraisal. Front Immunol. 2022;13:973702. https:\/\/doi.org\/10.3389\/fimmu.2022.973702.","journal-title":"Front Immunol"},{"issue":"11","key":"1052_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102661","volume":"19","author":"H Fang","year":"2020","unstructured":"Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmune Rev. 2020;19(11):102661. https:\/\/doi.org\/10.1016\/j.autrev.2020.102661.","journal-title":"Autoimmune Rev."},{"issue":"2","key":"1052_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","volume":"120","author":"S Gounni Abdelilah","year":"2006","unstructured":"Gounni Abdelilah S, Wellemans V, Agouli M, Guenounou M, Hamid Q, Beck LA, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease: role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220\u201331. https:\/\/doi.org\/10.1016\/j.clim.2006.03.014.","journal-title":"Clin Immunol"},{"key":"1052_CR51","doi-asserted-by":"publisher","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","volume":"10","author":"R Maglie","year":"2023","unstructured":"Maglie R, Solimani F, Didona D, Pipit\u00f2 C, Antiga E, Di Zenzo G. The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets. Front Med (Lausanne). 2023;10:1128154. https:\/\/doi.org\/10.3389\/fmed.2023.1128154.","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"1052_CR52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","volume":"180","author":"WJ Pickford","year":"2015","unstructured":"Pickford WJ, Gudi V, Haggart AM, Lewis BJ, Herriot R, Barker RN, et al. T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid. Clin Exp Immunol. 2015;180(2):189\u2013200. https:\/\/doi.org\/10.1111\/cei.12566.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1052_CR53","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/bjd.15924","volume":"177","author":"PC Freire","year":"2017","unstructured":"Freire PC, Mu\u00f1oz CH, Stingl G. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. Br J Dermatol. 2017;177(6):1644\u201353. https:\/\/doi.org\/10.1111\/bjd.15924.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1052_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdermsci.2024.03.009","volume":"114","author":"S Emtenani","year":"2024","unstructured":"Emtenani S, Linnemann BE, Recke A, von Georg A, Goletz S, Schmidt E, et al. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity. J Dermatol Sci. 2024;114(2):64\u201370. https:\/\/doi.org\/10.1016\/j.jdermsci.2024.03.009.","journal-title":"J Dermatol Sci"},{"issue":"1-2","key":"1052_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","volume":"346","author":"KAN Messingham","year":"2009","unstructured":"Messingham KAN, Noe MH, Chapman MA, Giudice GJ, Fairley JA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods. 2009;346(1\u20132):18\u201325. https:\/\/doi.org\/10.1016\/j.jim.2009.04.013.","journal-title":"J Immunol Methods"},{"issue":"4","key":"1052_CR56","first-page":"577","volume":"42","author":"R D\u00f6pp","year":"2000","unstructured":"D\u00f6pp R, Schmidt E, Chimanovitch I, Leverkus M, Br\u00f6cker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000;42(4):577\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1052_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamadermatol.2016.4593","volume":"153","author":"T Hashimoto","year":"2017","unstructured":"Hashimoto T, Tsuruta D, Ishii N. Immunoglobulin E autoantibodies in bullous pemphigoid detected by immunoglobulin E enzyme-linked immunosorbent assays. JAMA Dermatol. 2017;153(1):15\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2016.4593.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1052_CR58","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","volume":"193","author":"H Ujiie","year":"2014","unstructured":"Ujiie H, Sasaoka T, Izumi K, Nishie W, Shinkuma S, Natsuga K, et al. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation. J Immunol. 2014;193(9):4415\u201328. https:\/\/doi.org\/10.4049\/jimmunol.1400095.","journal-title":"J Immunol"},{"issue":"10","key":"1052_CR59","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3390\/jcm11102856","volume":"11","author":"M Afarideh","year":"2022","unstructured":"Afarideh M, Borucki R, Werth VP. A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets. J Clin Med. 2022;11(10):2856. https:\/\/doi.org\/10.3390\/jcm11102856.","journal-title":"J Clin Med"},{"issue":"9","key":"1052_CR60","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/ced\/llae067","volume":"49","author":"A Aguado V\u00e1zquez","year":"2024","unstructured":"Aguado V\u00e1zquez A, Est\u00e9banez Corrales A, Melgosa Ramos FJ, Mascar\u00f3 Galy JM, Fulgencio-Barbarin J, et al. Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience. Clin Exp Dermatol. 2024;49(9):1002\u20136. https:\/\/doi.org\/10.1093\/ced\/llae067.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1052_CR61","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/bjd\/ljad369","volume":"190","author":"R Chebani","year":"2024","unstructured":"Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguer M-A, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024;190(2):258\u201365. https:\/\/doi.org\/10.1093\/bjd\/ljad369.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1052_CR62","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu T, Wang Z, Xue Z, Wang Z, Zhang Y, Mi Z, et al. Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nat Commun. 2024;15(1):5949. https:\/\/doi.org\/10.1038\/s41467-024-50283-3.","journal-title":"Nat Commun"},{"issue":"4","key":"1052_CR63","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1365-2133.2008.08979.x","volume":"160","author":"C G\u00fcnther","year":"2009","unstructured":"G\u00fcnther C, Carballido-Perrig N, Kopp T, Carballido JM, Pfeiffer C. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course. Br J Dermatol. 2009;160(4):747\u201355. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08979.x.","journal-title":"Br J Dermatol"},{"key":"1052_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.718073","volume":"12","author":"T Zhou","year":"2021","unstructured":"Zhou T, Peng B, Geng S. Emerging biomarkers and therapeutic strategies for refractory bullous pemphigoid. Front Immunol. 2021;12:718073. https:\/\/doi.org\/10.3389\/fimmu.2021.718073.","journal-title":"Front Immunol"},{"key":"1052_CR65","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6716419","volume":"2017","author":"K Juczynska","year":"2017","unstructured":"Juczynska K, Wozniacka A, Waszczykowska E, Danilewicz M, Wagrowska-Danilewicz M, Wieczfinska J, et al. Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis. Mediators Inflamm. 2017;2017:6716419. https:\/\/doi.org\/10.1155\/2017\/6716419.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"1052_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/bjd\/ljaf219","volume":"193","author":"HY Chung","year":"2025","unstructured":"Chung HY, Chen CB, Lee HE, Lu CW, Chen WT, Hui RC, et al. Janus kinase\/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid. Br J Dermatol. 2025;193(3):521\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljaf219.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1052_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071019","volume":"13","author":"MM Limberg","year":"2023","unstructured":"Limberg MM, Weihrauch T, Gray N, Ernst N, Hartmann K, Raap U. Eosinophils, basophils, and neutrophils in bullous pemphigoid. Biomolecules. 2023;13(7):1019. https:\/\/doi.org\/10.3390\/biom13071019.","journal-title":"Biomolecules"},{"issue":"8","key":"1052_CR68","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","volume":"98","author":"U R\u00fcdrich","year":"2018","unstructured":"R\u00fcdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol. 2018;98(8):766\u201371. https:\/\/doi.org\/10.2340\/00015555-2951.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1052_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","volume":"83","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.060.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1052_CR70","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1046\/j.1365-2133.1999.02907.x","volume":"140","author":"MJ Rico","year":"1999","unstructured":"Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RP 3rd. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol. 1999;140(6):1079\u201386. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02907.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1052_CR71","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/bf02507102","volume":"288","author":"E Schmidt","year":"1996","unstructured":"Schmidt E, Bastian B, Dummer R, Tony HP, Br\u00f6cker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res. 1996;288(7):353\u20137. https:\/\/doi.org\/10.1007\/bf02507102.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1052_CR72","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","volume":"138","author":"F Ameglio","year":"1998","unstructured":"Ameglio F, D\u2019Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol. 1998;138(4):611\u20134. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02169.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1052_CR73","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol. 2024;25(2):195\u2013212. https:\/\/doi.org\/10.1007\/s40257-023-00832-1.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1052_CR74","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/bjd\/ljaf035","volume":"192","author":"R Maglie","year":"2025","unstructured":"Maglie R, Didona D, Solimani F, Pipit\u00f2 C, Baffa ME, Hertl M, et al. Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series. Br J Dermatol. 2025;192(6):1124\u20136. https:\/\/doi.org\/10.1093\/bjd\/ljaf035.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1052_CR75","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Acquilina S, Asero R, Baker D, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"17","key":"1052_CR76","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic spontaneous urticaria: a review. JAMA. 2024;332(17):1464\u201377. https:\/\/doi.org\/10.1001\/jama.2024.15568.","journal-title":"JAMA"},{"issue":"4","key":"1052_CR77","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2018.04.013","volume":"6","author":"SS Saini","year":"2018","unstructured":"Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil\u2019s itch. J Allergy Clin Immunol Pract. 2018;6(4):1097\u2013106. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.013.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1052_CR78","unstructured":"Dabija D, Tadi P, Danosos GN. Chronic urticaria. In: StatPearls. Treasure Island: StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555910\/. Accessed 28 Apr 2026."},{"issue":"8","key":"1052_CR79","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/03007995.2019.1586222","volume":"35","author":"B Hoskin","year":"2019","unstructured":"Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387\u201395. https:\/\/doi.org\/10.1080\/03007995.2019.1586222.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1052_CR80","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1111\/bjd.15347","volume":"177","author":"G Shalom","year":"2017","unstructured":"Shalom G, Magen E, Dreiher J, Freud T, Bogen B, Comaneshter D, et al. Chronic urticaria and atopic disorders: a cross-sectional study of 11 271 patients. Br J Dermatol. 2017;177(4):e96\u20137. https:\/\/doi.org\/10.1111\/bjd.15347.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1052_CR81","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/jdv.14210","volume":"31","author":"SF Thomsen","year":"2017","unstructured":"Thomsen SF, Pritzier EC, Anderson CD, Vaugelade-Baust N, Dodge R, Dahlborn A-K, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017;31(6):1048\u201355. https:\/\/doi.org\/10.1111\/jdv.14210.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1052_CR82","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F, Canonica W, Oude Elberink H, Gim\u00e9nez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005\u201316. https:\/\/doi.org\/10.1111\/all.13209.","journal-title":"Allergy"},{"issue":"10","key":"1052_CR83","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s13555-025-01498-9","volume":"15","author":"K Weller","year":"2025","unstructured":"Weller K, Winders TA, McCarthy J, Saraswat P, Chapman-Rothe N, Raftery T, et al. The Urticaria Voices Study: physicians\u2019 perspectives on the real-world patient burden, treatments, and outcomes in chronic spontaneous urticaria. Dermatol Therapy. 2025;15(10):2925\u201346. https:\/\/doi.org\/10.1007\/s13555-025-01498-9.","journal-title":"Dermatol Therapy"},{"key":"1052_CR84","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13601-015-0074-7","volume":"5","author":"M Ferrer","year":"2015","unstructured":"Ferrer M. Immunological events in chronic spontaneous urticaria. Clin Transl Allergy. 2015;5:30. https:\/\/doi.org\/10.1186\/s13601-015-0074-7.","journal-title":"Clin Transl Allergy"},{"issue":"5","key":"1052_CR85","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.all.0000182540.45348.bc","volume":"5","author":"J Sheikh","year":"2005","unstructured":"Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005;5(5):403\u20137. https:\/\/doi.org\/10.1097\/01.all.0000182540.45348.bc.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"9","key":"1052_CR86","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.jaip.2025.07.025","volume":"13","author":"SS Saini","year":"2025","unstructured":"Saini SS, Asero R, Cugno M, Park H-S, Oliver ET. Pathogenesis of chronic spontaneous urticaria with or without angioedema. J Allergy Clin Immunol Pract. 2025;13(9):2221\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2025.07.025.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1052_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","volume":"13","author":"S Altrichter","year":"2021","unstructured":"Altrichter S, Fok JS, Jiao Q, Kolkhir P, Pyatilova P, Romero SM, et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(2):206\u201318. https:\/\/doi.org\/10.4168\/aair.2021.13.2.206.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"1052_CR88","doi-asserted-by":"publisher","first-page":"608","DOI":"10.5114\/ada.2021.108910","volume":"38","author":"K Gomu\u0142ka","year":"2021","unstructured":"Gomu\u0142ka K, Wrze\u015bniak M, M\u0119drala W, Panaszek B. Basophils priming in patients with chronic spontaneous urticaria. Adv Dermatol Allergol. 2021;38(4):608\u201310. https:\/\/doi.org\/10.5114\/ada.2021.108910.","journal-title":"Adv Dermatol Allergol"},{"issue":"12","key":"1052_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210320","volume":"24","author":"Y Yanase","year":"2023","unstructured":"Yanase Y, Matsubara D, Takahagi S, Tanaka A, Ozawa K, Hide M. Basophil characteristics as a marker of the pathogenesis of chronic spontaneous urticaria in relation to the coagulation and complement systems. Int J Mol Sci. 2023;24(12):10320. https:\/\/doi.org\/10.3390\/ijms241210320.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1052_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/1865-1380-5-39","volume":"5","author":"JA Bernstein","year":"2012","unstructured":"Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012;5(1):39. https:\/\/doi.org\/10.1186\/1865-1380-5-39.","journal-title":"Int J Emerg Med"},{"key":"1052_CR91","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8163803","volume":"2016","author":"A Navin\u00e9s-Ferrer","year":"2016","unstructured":"Navin\u00e9s-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Mart\u00edn M. IgE-related chronic diseases and anti-IgE-based treatments. J Immunol Res. 2016;2016:8163803. https:\/\/doi.org\/10.1155\/2016\/8163803.","journal-title":"J Immunol Res"},{"issue":"3","key":"1052_CR92","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clim.2004.10.007","volume":"114","author":"M Caproni","year":"2005","unstructured":"Caproni M, Giomi B, Volpi W, Melani L, Schincaglia E, Macchia D, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol. 2005;114(3):284\u201392. https:\/\/doi.org\/10.1016\/j.clim.2004.10.007.","journal-title":"Clin Immunol"},{"issue":"5","key":"1052_CR93","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bjd.13621","volume":"172","author":"AB Kay","year":"2015","unstructured":"Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u2018idiopathic\u2019) urticaria. Br J Dermatol. 2015;172(5):1294\u2013302. https:\/\/doi.org\/10.1111\/bjd.13621.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1052_CR94","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/intimm\/8.9.1367","volume":"8","author":"H Toru","year":"1996","unstructured":"Toru H, Noroyama S, Suzuki K, Yata J, Nakahata T. Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol. 1996;8(9):1367\u201373. https:\/\/doi.org\/10.1093\/intimm\/8.9.1367.","journal-title":"Int Immunol"},{"issue":"5","key":"1052_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nri2072","volume":"7","author":"S Kraft","year":"2007","unstructured":"Kraft S, Kinet J-P. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365\u201378. https:\/\/doi.org\/10.1038\/nri2072.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1052_CR96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00403-024-02966-6","volume":"316","author":"S Ho\u015fg\u00f6ren-Tekin","year":"2024","unstructured":"Ho\u015fg\u00f6ren-Tekin S, Ey\u00fcbo\u011flu IP, Akkiprik M, Gim\u00e9nez-Arnau AM, Salman A. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria. Arch Dermatol Res. 2024;316(6):261. https:\/\/doi.org\/10.1007\/s00403-024-02966-6.","journal-title":"Arch Dermatol Res"},{"key":"1052_CR97","unstructured":"Xolair: highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf. Accessed 28 Apr 2026."},{"issue":"11","key":"1052_CR98","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","volume":"13","author":"TB Casale","year":"2023","unstructured":"Casale TB, Gim\u00e9nez-Arnau AM, Bernstein JA, Holden M, Zuberbier T, et al. Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol Ther (Heildelb). 2023;13(11):2573\u201388. https:\/\/doi.org\/10.1007\/s13555-023-01040-9.","journal-title":"Dermatol Ther (Heildelb)."},{"issue":"2","key":"1052_CR99","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","volume":"137","author":"A Kaplan","year":"2016","unstructured":"Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2015.08.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1052_CR100","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jcm12010378","volume":"12","author":"CA Maronese","year":"2023","unstructured":"Maronese CA, Ferrucci SM, Moltrasio C, Lorini M, Carbonelli V, Asero R, et al. IgG and IgE autoantibodies to IgE receptors in chronic spontaneous urticaria and their role in the response to omalizumab. J Clin Med. 2023;12(1):378. https:\/\/doi.org\/10.3390\/jcm12010378.","journal-title":"J Clin Med"},{"key":"1052_CR101","unstructured":"Rhapsido: highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218436s000lbl.pdf. Accessed 28 Apr 2026."},{"issue":"10","key":"1052_CR102","doi-asserted-by":"publisher","first-page":"98494","DOI":"10.1056\/nejmoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):98494. https:\/\/doi.org\/10.1056\/nejmoa2408792.","journal-title":"N Engl J Med"},{"issue":"4","key":"1052_CR103","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","volume":"85","author":"P Kolkhir","year":"2025","unstructured":"Kolkhir P, Fok JS, Kocat\u00fcrk E, Li PH, Okas TL, Marcelino J, et al. Update on the treatment of chronic spontaneous urticaria. Drugs. 2025;85(4):475\u201386. https:\/\/doi.org\/10.1007\/s40265-025-02170-4.","journal-title":"Drugs"},{"issue":"9","key":"1052_CR104","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","volume":"14","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Laws E, Maloney J, et al. Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels. Dermatol Ther (Heidelb). 2024;14(9):2427\u201341. https:\/\/doi.org\/10.1007\/s13555-024-01231-y.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"1052_CR105","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.anai.2022.08.594","volume":"129","author":"K Hayama","year":"2022","unstructured":"Hayama K, Ramsey A, Maurer M, Hide M, Lheritier K, Zharkov A, et al. Remibrutinib improves chronic spontaneous urticaria in patients with low or high IgE. Ann Allergy Asthma Immunol. 2022;129(5):S31\u20132.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1052_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.02.018","author":"M Metz","year":"2026","unstructured":"Metz M, Mitha E, Leflein J, Talreja N, Gotua M, Krasowska D, et al. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2026. https:\/\/doi.org\/10.1016\/j.jaci.2026.02.018.","journal-title":"J Allergy Clin Immunol"},{"key":"1052_CR107","unstructured":"Celldex Therapeutics. A phase 3 randomized, double-blind, placebo-controlled study to sssess the efficacy and safety of\u00a0barzolvolimab\u00a0in patients with\u00a0chronic\u00a0spontaneous\u00a0urticaria\u00a0who remain symptomatic despite H1 antihistamine treatment (EMBARQ-CSU1). ClinicalTrials.gov identifier: NCT06445023. Updated March, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06445023. Accessed 20 May 2026."},{"key":"1052_CR108","unstructured":"Celldex Therapeutics. A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of\u00a0barzolvolimab\u00a0in patients with\u00a0chronic\u00a0spontaneous\u00a0urticaria\u00a0who remain symptomatic despite H1 antihistamine treatment (EMBARQ-CSU2). ClinicalTrials.gov identifier: NCT06455202. Updated March, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06455202. Accessed 20 May 2026."},{"issue":"6","key":"1052_CR109","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","volume":"155","author":"J McLaren","year":"2025","unstructured":"McLaren J, Chon Y, Gorski KS, Bernstein JA, Corren J, Hayama K, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025;155(6):1945\u201356. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.045.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1052_CR110","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jaip.2025.06.014","volume":"13","author":"J Phillipps","year":"2025","unstructured":"Phillipps J, Bhasin A, Sluzevich J. Exploring mepolizumab use in chronic spontaneous urticaria: an open-label, single-arm, exploratory study. J Allergy Clin Immunol Pract. 2025;13(9):2503\u20135.e1. https:\/\/doi.org\/10.1016\/j.jaip.2025.06.014.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"1052_CR111","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277\u201384. https:\/\/doi.org\/10.1111\/ced.14722.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1052_CR112","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.025.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1052_CR113","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059\u201365. https:\/\/doi.org\/10.1111\/jdv.14570.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1052_CR114","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/bjd\/ljaf213","volume":"193","author":"SG Kwatra","year":"2025","unstructured":"Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol. 2025;193(4):642\u201352. https:\/\/doi.org\/10.1093\/bjd\/ljaf213.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1052_CR115","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","volume":"79","author":"E Boozalis","year":"2018","unstructured":"Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, St\u00e4nder S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018;79(4):714\u20139.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.047.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1052_CR116","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2022;86(3):573\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.036.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1052_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6040097","volume":"6","author":"CD Kwon","year":"2019","unstructured":"Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines (Basel). 2019;6(4):97. https:\/\/doi.org\/10.3390\/medicines6040097.","journal-title":"Medicines (Basel)"},{"issue":"6","key":"1052_CR118","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"V Liao","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024;190(6):798\u2013810. https:\/\/doi.org\/10.1093\/bjd\/ljae052.","journal-title":"Br J Dermatol"},{"key":"1052_CR119","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","volume":"14","author":"Y Shao","year":"2023","unstructured":"Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, et al. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol. 2023;14:1301817. https:\/\/doi.org\/10.3389\/fimmu.2023.1301817.","journal-title":"Front Immunol"},{"issue":"20","key":"1052_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012390","volume":"23","author":"L-S Wong","year":"2022","unstructured":"Wong L-S, Yen Y-T. Chronic nodular prurigo: an update on the pathogenesis and treatment. Int J Mol Sci. 2022;23(20):12390. https:\/\/doi.org\/10.3390\/ijms232012390.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1052_CR121","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams KA, Roh YS, Brown I, Sutaria N, Bakhshi P, Choi J, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67\u201377. https:\/\/doi.org\/10.1080\/17512433.2021.1852080.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1052_CR122","unstructured":"Mullins TB, Sharma P, Riley CA, Syed HA, Sonthalia S. Prurigo nodularis. In: StatPearls. Treasure Island: StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459204\/. Accessed 12 Nov 2025."},{"issue":"1","key":"1052_CR123","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jaci.2023.11.003","volume":"153","author":"C Conrad","year":"2024","unstructured":"Conrad C, Schlapbach C. Prurigo nodularis forecast: light type 2 inflammation with high chances of fibrosis. J Allergy Clin Immunol. 2024;153(1):93\u20134. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1052_CR124","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1111\/jocd.14709","volume":"21","author":"D Agrawal","year":"2022","unstructured":"Agrawal D, Sardana K, Mathachan SR, Bhardwaj M, Ahuja A, Jain S. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol. 2022;21(9):4009\u201315. https:\/\/doi.org\/10.1111\/jocd.14709.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"1052_CR125","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","volume":"165","author":"S Fukushi","year":"2011","unstructured":"Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10498.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1052_CR126","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.anai.2023.08.008","volume":"131","author":"KL Auyeung","year":"2023","unstructured":"Auyeung KL, Kim BS. Emerging concepts in neuropathic and neurogenic itch. Ann Allergy Asthma Immunol. 2023;131(5):561\u20136. https:\/\/doi.org\/10.1016\/j.anai.2023.08.008.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"23","key":"1052_CR127","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1007\/s00018-017-2647-1","volume":"74","author":"H Murota","year":"2017","unstructured":"Murota H, Lingli Y, Katayama I. Periostin in the pathogenesis of skin diseases. Cell Mol Life Sci. 2017;74(23):4321\u20138. https:\/\/doi.org\/10.1007\/s00018-017-2647-1.","journal-title":"Cell Mol Life Sci"},{"key":"1052_CR128","doi-asserted-by":"publisher","unstructured":"Hashimoto T, Nattkemper LA, Sung Kim H, Kursewicz CD, Fowler E, Shah SM, et al. Dermal periostin: a new player in itch of prurigo nodularis. Acta Derm Venereol. 2021;101(1):adv00375. https:\/\/doi.org\/10.2340\/00015555-3702.","DOI":"10.2340\/00015555-3702"},{"issue":"5","key":"1052_CR129","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.clindermatol.2025.03.008","volume":"43","author":"SG Brooks","year":"2025","unstructured":"Brooks SG, Yosipovitch G. Evolving evidence in the neural sensitization of prurigo nodularis. Clin Dermatol. 2025;43(5):626\u201332. https:\/\/doi.org\/10.1016\/j.clindermatol.2025.03.008.","journal-title":"Clin Dermatol"},{"key":"1052_CR130","unstructured":"Nemluvio: highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761391s001s002lbl.pdf. Accessed 28 Apr 2026."},{"issue":"7","key":"1052_CR131","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s13555-025-01437-8","volume":"15","author":"G Licata","year":"2025","unstructured":"Licata G, Arisi M, Giorgio CM, Ariasi C, Tomasi C, Soglia S, et al. Emerging therapies in the treatment of prurigo nodularis: biological therapy and systematic review of literature. Dermatol Ther (Heidelb). 2025;15(7):1705\u201318. https:\/\/doi.org\/10.1007\/s13555-025-01437-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1052_CR132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/jamadermatol.2025.4950","volume":"162","author":"S Stander","year":"2026","unstructured":"Stander S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, et al. Vixarelimab in patients with prurigo nodularis: a randomized clinical trial. JAMA Dermatol. 2026;162(2):133\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2025.4950.","journal-title":"JAMA Dermatol"},{"key":"1052_CR133","unstructured":"Kwatra SG, Metz M, Yosipovitch G, Brown K, Biguenet S, Halden P, et al. Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: 40-week results from a randomised, double-blind, placebo-controlled phase 2 study. In: Presented at: 33rd European Academy of Dermatology and Venereology Congress; 25\u201328 September, 2024; Amsterdam."},{"key":"1052_CR134","unstructured":"Incyte Corporation. A phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of\u00a0povorcitinib\u00a0in participants with\u00a0prurigo\u00a0nodularis (STOP-PN1). ClinicalTrials.gov identifier: NCT06516952. Updated May, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06516952. Accessed 20 May 2026."},{"key":"1052_CR135","unstructured":"Incyte Corporation. A phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of\u00a0povorcitinib\u00a0in participants with\u00a0prurigo\u00a0nodularis (STOP-PN2). ClinicalTrials.gov identifier: NCT06516965. Updated April, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06516965. Accessed 20 May 2026."},{"issue":"5","key":"1052_CR136","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jaad.2019.06.038","volume":"81","author":"BS Kim","year":"2019","unstructured":"Kim BS, Berger TG, Yosipovitch G. Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment. J Am Acad Dermatol. 2019;81(5):1223\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.038.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1052_CR137","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2340\/00015555-3892","volume":"101","author":"MP Pereira","year":"2021","unstructured":"Pereira MP, Farcas A, Zeidler C, St\u00e4nder S. Chronic pruritus of unknown origin: clinical profile and disease-related burden. Acta Derm Venereol. 2021;101(9):225. https:\/\/doi.org\/10.2340\/00015555-3892.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1052_CR138","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jaad.2015.11.029","volume":"74","author":"AZ Xu","year":"2016","unstructured":"Xu AZ, Tripathi SV, Kau AL, Schaffer A, Kim BS. Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus. J Am Acad Dermatol. 2016;74(5):1017\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2015.11.029.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"1052_CR139","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2024.4899","volume":"331","author":"DC Butler","year":"2024","unstructured":"Butler DC, Berger T, Elmariah S, Kim B, Chisolm S, Kwatra SG, et al. Chronic pruritus: a review. JAMA. 2024;331(24):2114\u201324. https:\/\/doi.org\/10.1001\/jama.2024.4899.","journal-title":"JAMA"},{"issue":"9","key":"1052_CR140","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.3390\/ijms24097956","volume":"24","author":"V Papa","year":"2023","unstructured":"Papa V, Li Pomi F, Borgia F, Vaccaro M, Pioggia G, Gangemi S. Immunosenescence and skin: a state of art of its etiopathogenetic role and crucial watershed for systemic implications. Int J Mol Sci. 2023;24(9):7956. https:\/\/doi.org\/10.3390\/ijms24097956.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1052_CR141","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2021.09.014","volume":"149","author":"AM Trier","year":"2022","unstructured":"Trier AM, Mack MR, Fredman A, Tamari M, Ver Heul AM, Zhao Y, et al. IL-33 signaling in sensory neurons promotes dry skin itch. J Allergy Clin Immunol. 2022;149(4):1473\u201380.e6. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.014.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1052_CR142","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/dad.0000000000001902","volume":"43","author":"C Dehner","year":"2021","unstructured":"Dehner C, Chen L, Kim B, Rosman IS. Chronic itch of unknown origin is associated with an enhanced Th2 skin immune profile. Am J Dermatopathol. 2021;43(11):773\u20135. https:\/\/doi.org\/10.1097\/dad.0000000000001902.","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"1052_CR143","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaad.2025.01.031","volume":"92","author":"J Manjunath","year":"2025","unstructured":"Manjunath J, Bao A, Gonzalez W, Vojvoda E, D\u2019Amiano AJ, Patel S, et al. Comprehensive plasma cytokine profiling reveals a distinct endotype of type 2 inflammation in chronic pruritus of unknown origin. J Am Acad Dermatol. 2025;92(6):1365\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.031.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1052_CR144","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"E-B Haddad","year":"2022","unstructured":"Haddad E-B, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(7):1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1052_CR145","doi-asserted-by":"publisher","first-page":"117727192094071","DOI":"10.1177\/1177271920940712","volume":"15","author":"K Salao","year":"2020","unstructured":"Salao K, Sawanyawisuth K, Winaikosol K, Choonhakarn C, Chaowattanapanit S. Interleukin-31 and chronic pruritus of unknown origin. Biomark Insights. 2020;15:1177271920940712. https:\/\/doi.org\/10.1177\/1177271920940712.","journal-title":"Biomark Insights."},{"issue":"6","key":"1052_CR146","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jaad.2025.08.006","volume":"93","author":"YM Akiska","year":"2025","unstructured":"Akiska YM, Bao A, Gage D, Shahsavari S, Yossef SM, Born LJ, et al. Systemic immune profiling identifies elevated mas-related G-coupled receptor membrane X2 (MRGPRX2) with a distinct inflammatory signature in chronic pruritus of unknown origin. J Am Acad Dermatol. 2025;93(6):1566\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.006.","journal-title":"J Am Acad Dermatol"},{"key":"1052_CR147","unstructured":"Sanofi. Efficacy and safety\u00a0of\u00a0subcutaneous\u00a0dupilumab\u00a0for the treatment\u00a0of\u00a0adult participants with chronic pruritus of unknown origin (CPUO) (LIBERTY-CPUO-CHIC). ClinicalTrials.gov identifier: NCT05263206. Updated April, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05263206. Accessed 20 May 2026."},{"key":"1052_CR148","unstructured":"Galderma R&D. Proof\u00a0of\u00a0concept study to assess the pharmacokinetics\/pharmacodynamics\u00a0of\u00a0nemolizumab\u00a0in adults with\u00a0chronic\u00a0pruritus\u00a0of\u00a0unknown\u00a0origin\u00a0(CPUO) (CPUO). ClinicalTrials.gov identifier: NCT07074977. Updated May, 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07074977. Accessed 20 May 2026."},{"issue":"7","key":"1052_CR149","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","volume":"160","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Bordeaux ZA, Parthasarathy V, Kollhoff AL, Alajmi A, Pritchard T, et al. Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial. JAMA Dermatol. 2024;160(7):717\u201324. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1464.","journal-title":"JAMA Dermatol"},{"issue":"21","key":"1052_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110720","volume":"26","author":"V Pala","year":"2025","unstructured":"Pala V, Rosset F, Mastorino L, Sciamarrelli N, Boskovic S, Borriello S, et al. The central role of Th2 immune response in inflammatory dermatoses: from pathogenesis to targeted therapies. Int J Mol Sci. 2025;26(21):10720. https:\/\/doi.org\/10.3390\/ijms262110720.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1052_CR151","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.anai.2025.09.014","volume":"136","author":"G Coscarella","year":"2026","unstructured":"Coscarella G, Edwards E, Yosipovitch G. Basic mechanisms of itch and advances in clinical management. Ann Allergy Asthma Immunol. 2026;136(2):131\u201340. https:\/\/doi.org\/10.1016\/j.anai.2025.09.014.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1052_CR152","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","volume":"152","author":"L Misery","year":"2023","unstructured":"Misery L, Pierre O, Le Gall-Ianotto C, Lebonvallet N, Chernyshov PV, Le Garrec R, et al. Basic mechanisms of itch. J Allergy Clin Immunol. 2023;152(1):11\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1052_CR153","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/exd.14014","volume":"28","author":"C Nakashima","year":"2019","unstructured":"Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405\u201311. https:\/\/doi.org\/10.1111\/exd.14014.","journal-title":"Exp Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01052-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01052-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01052-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:32:05Z","timestamp":1789464725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01052-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":153,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01052-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enno Schmidt received research funding from Admirx, Almirall, Alpine Immune, Argenx, AstraZeneca, Bayer, Biotest, CSL, Domp\u00e9, Euroimmun, Fresenius Medical Care, Incyte, Pharmaxis, and Sanofi and is a speaker for and\/or received consulting fees from AbbVie, Argenx, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Fresenius Medical Care, Janssen, and Sanofi. Marta Ferrer Puga received research funding from the Carlos III Health Institute (ISCIII), Novartis, and Thematic Networks for Cooperative Research Centres; and is a speaker for and\/or received consulting fees from Celldex, Celltrion, FAES, Genentech, Menarini, MSD, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Uriach. Brian S. Kim is Chair of the Scientific Advisory Board for Alys Pharmaceuticals; co-founder of Attu Therapeutics, Neurommune Therapeutics; Data Safety Monitoring Committee member for AbbVie and Advarra; reviewer for Almirall, Anvia Therapeutics, Atlas Venture, Bain Capital, Cara Therapeutics, Catalys Pacific, Clexio Biosciences, Elanco, Eli Lilly, Escient Pharmaceuticals, Evommune, Galderma, General Atlantic, Gilead Sciences, Goldman Sachs Life Sciences, Guidepoint Global, and Korea US Collaborative Research Fund; steering committee member for LEO Pharma; consultant for Medicxi, Monte Rosa Therapeutics, Neurocrine Biosciences, Novartis, OrbiMed, Pfizer, Quilt Bio, Recludix Pharma, Regeneron, ResearchHub Foundation, Sanofi, Schr\u00f6dinger, Septerna, Triveni Bio, and Vida Ventures; scientific advisory board member for Attovia Therapeutics, Cell Reports Medicine, Neurocrine Biosciences, and Triveni Bio; editorial board member for the\n                      Journal of Allergy and Clinical Immunology\n                      ; stockholder at ABRAX Japan, Alys Pharmaceuticals, Locus Biosciences, Recens Medical, and Triveni Bio; and received research grants from Eli Lilly and Triveni Bio. Eric L. Simpson received grants or served as principal investigator from\/for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi, Target, and VeriSkin; and received personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evommune, FIDE, Impetus Healthcare, Incyte, Inmagene Biopharmaceuticals, Innovaderm Recherches\/Indero, Janssen, LectureLinx (LLX), LEO, Numab Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi, and Sitryx Therapeutics.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors provided critical feedback on the manuscript, approved the final manuscript for submission, read and approved the final version, and are accountable for the accuracy and integrity of the manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}